See more : ACCENTRO Real Estate AG (A4Y.DE) Income Statement Analysis – Financial Results
Complete financial analysis of Ikena Oncology, Inc. (IKNA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ikena Oncology, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Indel B S.p.A. (INDB.MI) Income Statement Analysis – Financial Results
- Cindrella Hotels Limited (CINDHO.BO) Income Statement Analysis – Financial Results
- ISHIN CO LTD (143A.T) Income Statement Analysis – Financial Results
- Persistent Systems Limited (PERSISTENT.NS) Income Statement Analysis – Financial Results
- Prairie Provident Resources Inc. (PPR.TO) Income Statement Analysis – Financial Results
Ikena Oncology, Inc. (IKNA)
About Ikena Oncology, Inc.
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 9.16M | 15.62M | 30.99M | 9.19M | 13.75M | 990.00K |
| Cost of Revenue | 1.02M | 2.03M | 47.11M | 44.85M | 24.94M | 38.99M |
| Gross Profit | 8.14M | 13.58M | -16.12M | -35.65M | -11.19M | -38.00M |
| Gross Profit Ratio | 88.86% | 86.98% | -52.03% | -387.79% | -81.33% | -3,837.98% |
| Research & Development | 59.65M | 64.32M | 47.11M | 44.85M | 24.94M | 38.56M |
| General & Administrative | 24.93M | 22.20M | 18.02M | 8.87M | 7.31M | 2.90M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 24.93M | 22.20M | 18.02M | 8.87M | 7.31M | 2.90M |
| Other Expenses | 0.00 | -10.00K | 23.00K | 263.00K | 1.68M | 0.00 |
| Operating Expenses | 84.58M | 86.52M | 65.12M | 53.71M | 32.25M | 41.46M |
| Cost & Expenses | 84.58M | 86.52M | 65.12M | 53.71M | 32.25M | 41.88M |
| Interest Income | 7.11M | 2.15M | 23.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 2.15M | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.02M | 2.03M | 1.72M | 1.26M | 122.00K | 422.00K |
| EBITDA | -74.40M | -70.15M | -33.59M | -44.22M | -18.25M | -40.44M |
| EBITDA Ratio | -812.19% | -449.18% | -108.42% | -480.95% | -132.69% | -4,088.08% |
| Operating Income | -75.42M | -70.90M | -34.14M | -44.52M | -18.49M | -40.89M |
| Operating Income Ratio | -823.33% | -453.99% | -110.18% | -484.22% | -134.46% | -4,130.71% |
| Total Other Income/Expenses | 7.09M | 2.14M | 23.00K | 263.00K | 1.68M | 29.00K |
| Income Before Tax | -68.33M | -68.77M | -34.12M | -44.26M | -16.82M | -40.87M |
| Income Before Tax Ratio | -745.94% | -440.29% | -110.10% | -481.36% | -122.28% | -4,127.78% |
| Income Tax Expense | -162.00K | -2.14M | 307.44K | 93.70K | 71.14K | 0.00 |
| Net Income | -68.17M | -66.63M | -34.12M | -44.26M | -16.82M | -40.87M |
| Net Income Ratio | -744.17% | -426.60% | -110.10% | -481.36% | -122.28% | -4,127.78% |
| EPS | -1.63 | -1.84 | -0.95 | -1.23 | -0.47 | -1.14 |
| EPS Diluted | -1.63 | -1.84 | -0.95 | -1.23 | -0.47 | -1.14 |
| Weighted Avg Shares Out | 41.74M | 36.19M | 35.98M | 35.85M | 35.85M | 35.85M |
| Weighted Avg Shares Out (Dil) | 41.74M | 36.19M | 35.98M | 35.85M | 35.85M | 35.85M |
Ikena Oncology Reports Third Quarter 2024 Financial Results
Strong financial position with $138 million in cash and investments at close of third quarter Strong financial position with $138 million in cash and investments at close of third quarter
Ikena Oncology Reports Second Quarter 2024 Financial Results
Strong financial position with $145 million in cash and investments at close of second quarter Strong financial position with $145 million in cash and investments at close of second quarter
Best Momentum Stocks to Buy for July 12th
IKNA, AVAH, and VEL made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 12, 2024.
New Strong Buy Stocks for July 12th
USAC, NHYDY, APOG, IKNA, and CRGY have been added to the Zacks Rank #1 (Strong Buy) List on July 12, 2024.
UPDATE – Ikena Oncology Announces Strategic Update
Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million; Exploring strategic options to maximize shareholder value BOSTON, May 28,...
Ikena Oncology Announces Strategic Update
Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million; Exploring strategic options to maximize shareholder value BOSTON, May 28,...
Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update
Strong financial position with $157.3 million; runway into 2H 2026 IK-930 program on track to deliver clinical update in 2H 2024 IK-595 program continues dose escalation in patients with RAS and RAF mutant cancers BOSTON, May 13, 2024 (GLOBE NEWSWIRE)...
Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum
BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will present a corporate overview at the Stifel 2024 Targeted Oncology...
Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
IK-930 continues to advance in the clinic now with an optimized formulation with improved pharmacokinetics IK-930 clinical update planned for 2H 2024 including additional data from EHE patients in dose escalation and initial mesothelioma patient data IK-595 Phase I dose...
Ikena Oncology to Participate in TD Cowen 44th Annual Health Care Conference
BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will participate in a targeted oncology panel at the TD Cowen...
Source: https://incomestatements.info
Category: Stock Reports